NCT00140972已完成4 期
A Multicenter, Randomized, Parallel-group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 mg Once Daily Versus Diclofenac Sodium 75 mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 160
- 主要终点
- WOMAC pain subscale
研究概览
简要总结
A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chinese males or females at least 40 years of age with osteoarthritis of the knee or hip
排除标准
- 未提供
结局指标
主要结局
WOMAC pain subscale
次要结局
- WOMAC Physical function subscale; WOMAC Stiffness subscale; Patient Global Assessment of Response to Therapy; Investigator Global Assessment of Disease Status
研究者
相似试验
已完成
3 期
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)OsteoarthritisNCT00542087Organon and Co516
已完成
4 期
Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and IbuprofenOsteoarthritis, KneeNCT00638807Pfizer's Upjohn has merged with Mylan to form Viatris Inc.388
已完成
4 期
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)Rheumatoid ArthritisNCT00157872Merck Sharp & Dohme LLC150
已完成
4 期
Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee OsteoarthritisOsteoarthritis, KneeNCT00643799Pfizer's Upjohn has merged with Mylan to form Viatris Inc.586
撤回
4 期
A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)OsteoarthritisNCT01429168Organon and Co